EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Revealing the Patient Perspective: Evolution of Patient‐Reported Outcome Measures in Botulinum Toxin Studies in Aesthetic Medicine

Steven Dayan, Alexander Z Rivkin, Patricia Ogilvie, Jean D A Carruthers, Yan Wu, Elisabeth Lee, Vaishali Patel, Maria Musumeci

Journal of Cosmetic Dermatology · 2025

DOI: 10.1111/jocd.70311 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Cosmetic Dermatology, 2025. Verfasst von Steven Dayan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology, University of Illinois at Chicago, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Patient Reported Outcome Measures, Botulinum Toxins, Type A, Cosmetic Techniques, Skin Aging. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Allergan Aesthetics, an AbbVie company, Allergan Aesthetics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

OnabotulinumtoxinA has been licensed for the treatment of upper facial lines for over 20 years. Patient benefits extend well beyond correction of the lines themselves—including positive effects on confidence, self‐esteem, feelings of attractiveness, and age appearance. Regulatory bodies recommend that patient‐reported outcomes (PROs) are routinely included in registrational studies to ensure the patient perspective is considered. Essential guidance is available from regulators and other expert groups to aid the development, validation, and use of appropriate PROs.

Aims

To reflect on the evolution of patient experience data collection in onabotulinumtoxinA aesthetic medicine development programs within the context of PRO usage across approved botulinum toxins.

Methods

Literature searches were performed to identify relevant publications.

Results

Several PRO instruments have been rigorously developed and validated following regulatory guidance and implemented in onabotulinumtoxinA clinical programs. These include the Facial Line Outcomes Questionnaire (FLO‐11) and Facial Line Satisfaction Questionnaire (FLSQ). The data generated have supported the licensing process and enabled a deeper understanding of patient perspectives. Although these instruments were developed for clinical studies, the concepts obtained directly from patient interviews align with patient goals in clinical practice. Similarly, PROs such as FACE‐Q are now employed more widely across approved botulinum toxins.

Conclusions

A patient‐centric approach, in lockstep with regulatory requirements, has been central to onabotulinumtoxinA development. Awareness of the comprehensive benefits of aesthetic treatments should continue to improve based on increasingly robust PROs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Patient Reported Outcome MeasuresBotulinum Toxins, Type ACosmetic TechniquesSkin AgingNeuromuscular AgentsHumansPatient SatisfactionSurveys and QuestionnairesEsthetics

Stichwörter der Autor:innen

botulinum neurotoxin type Aforehead linesglabellar lineslateral canthal linesonabotulinumtoxinApatient‐focused drug developmentpatient‐reported outcomes

Substanzen

Botulinum Toxins, Type Aonabotulinum toxin ANeuromuscular Agents

Autor:innen und Institutionen

  • Division of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology, University of Illinois at Chicago, Chicago, Illinois, USA.
  • DeNova Research, Chicago, Illinois, USA.
  • David Geffen/UCLA School of Medicine, University of California at Los Angeles, Los Angeles, California, USA.
  • Private Practice, Skin Concept, Munich, Germany.
  • Department of Ophthalmology, University of British Columbia, Vancouver, British Columbia, Canada.
  • Peking University First Hospital, Beijing, China.

Förderung

  • Allergan Aesthetics, an AbbVie company
  • Allergan Aesthetics

Zitieren

APA

Dayan, S., Rivkin, A. Z., Ogilvie, P., Carruthers, J. D. A., Wu, Y., Lee, E., Patel, V., & Musumeci, M. (2025). Revealing the Patient Perspective: Evolution of Patient‐Reported Outcome Measures in Botulinum Toxin Studies in Aesthetic Medicine. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.70311

Vancouver

Dayan S, Rivkin AZ, Ogilvie P, Carruthers JDA, Wu Y, Lee E, et al. Revealing the Patient Perspective: Evolution of Patient‐Reported Outcome Measures in Botulinum Toxin Studies in Aesthetic Medicine. Journal of Cosmetic Dermatology. 2025. doi:10.1111/jocd.70311

BibTeX
@article{Dayan2025,
  author = {Dayan, Steven and Rivkin, Alexander Z and Ogilvie, Patricia and Carruthers, Jean D A and Wu, Yan and Lee, Elisabeth and Patel, Vaishali and Musumeci, Maria},
  title = {Revealing the Patient Perspective: Evolution of Patient‐Reported Outcome Measures in Botulinum Toxin Studies in Aesthetic Medicine},
  journal = {Journal of Cosmetic Dermatology},
  year = {2025},
  doi = {10.1111/jocd.70311}
}
Kostenlos starten →